Detalhe da pesquisa
1.
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Medicina (Kaunas)
; 55(12)2019 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31766556
2.
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Medicina (Kaunas)
; 55(10)2019 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31627433
3.
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Medicina (Kaunas)
; 55(10)2019 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31640191
4.
Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
Anticancer Drugs
; 26(10): 1017-25, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26241803
5.
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.
Int J Mol Sci
; 14(10): 19731-62, 2013 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24084722
6.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Cancer Invest
; 30(1): 65-71, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22236191
7.
Immune system and bone microenvironment: rationale for targeted cancer therapies.
Oncotarget
; 11(4): 480-487, 2020 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32064051
8.
Immunotherapeutic approaches for hepatocellular carcinoma.
Oncotarget
; 8(20): 33897-33910, 2017 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28420805
9.
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
Crit Rev Oncol Hematol
; 95(1): 46-61, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25656744
10.
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Expert Opin Ther Targets
; 19(12): 1623-35, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26212068
11.
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.
Onco Targets Ther
; 8: 1345-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26089683
12.
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
J Immunother
; 37(1): 26-35, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24316553
13.
Systemic treatment of gastrointestinal cancer in elderly patients.
J Gastrointest Cancer
; 44(1): 22-32, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150086
14.
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
Clin Cancer Res
; 18(3): 850-7, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22142823
15.
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Cancer Biol Ther
; 12(2): 112-8, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21525780
16.
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
Prostate Cancer
; 2011: 258689, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22096653
17.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Cancer Biol Ther
; 9(9): 685-93, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20697196
18.
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
J Immunother
; 33(4): 435-41, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20386463